Objective The GLUCOSTAT project will develop a first to the market, fully integrated, biotechnology device that will enable automaticcontrol of blood glucose levels for patients in ICUs. This will improve the clinical outcomes for the patient as their bloodglucose concentration will be maintained in the healthy normal concentration range (4-6 mM). Automatic blood glucosecontrol will also decrease the workload on nurses as they no longer need to take frequent blood samples which will allow thisvaluable resource to be re-directed to more valuable roles within the intensive care wards. A move away from discretesampling to an automatic control system that maintains low fluctuations will result in a cost reduction of €2,638 per intensivecare unit (ICU) patient and hence be more resource and labour efficient. With an estimated 1.25 million sepsis/diabetespatients in the EU who will most benefit from continuous glucose monitoring (CGM), the total cost savings of implementingGLUCOSTAT will be in the order of €3.3 billion.The GLUCOSTAT project will optimise FLOW’s existing Diramo system and process used for its manufacture, and integratethe advanced control algorithm from Technical University of Denmark (DTU) to enable FLOW to apply for CE certification.The performance of the optimised CE marked device will then be evaluated by performing a clinical study where we willautomatically control the blood glucose level of ICU patients to stay within the normal 4-6 mM range. This will demonstratethe automated blood glucose control system’s effectiveness in terms of delivering good accuracy, usability and robustness,which will enable FLOW to carry out post project commercialisation and market activities. Once the automatic control systemhas been launched, penetrated the market, and proved itself in patients with sepsis and diabetes, a market potential of €4.5billion can be achieved for FLOW by implementing the device across all ICU patients in the EU and USA. Fields of science medical and health sciencesclinical medicinecritical care medicinemedical and health sciencesclinical medicineendocrinologydiabetesmedical and health sciencesmedical biotechnologytissue engineeringartificial pancreascontinuous glucose monitorssocial scienceseconomics and businessbusiness and managementcommerce Keywords biomarker blood glucose Intensive care units concentration measurement system prototype clinical trial Programme(s) H2020-EU.2.1.4. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Biotechnology Main Programme H2020-EU.2.3.1. - Mainstreaming SME support, especially through a dedicated instrument Topic(s) SMEInst-03-2016-2017 - Dedicated support to biotechnology SMEs closing the gap from lab to market Call for proposal H2020-SMEInst-2016-2017 See other projects for this call Sub call H2020-SMEINST-2-2016-2017 Funding Scheme SME-2 - SME instrument phase 2 Coordinator FLOWSION AS Net EU contribution € 2 499 796,25 Address AGTOFTSVEJ 3 D 6400 SONDERBORG Denmark See on map SME The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed. Yes Region Danmark Syddanmark Sydjylland Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Links Contact the organisation Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Total cost € 3 571 137,50
